Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
137 hedge funds and large institutions have $1.17B invested in Eagle Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 28 closing their positions.
177% more call options, than puts
Call options by funds: $17.5M | Put options by funds: $6.33M
75% more capital invested
Capital invested by funds: $667M → $1.17B (+$502M)
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more funds holding
Funds holding: 116 → 137 (+21)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$38.2M |
| 2 |
First Eagle Investment Management
New York
|
+$31.5M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$19.8M |
| 4 |
PC
PointState Capital
New York
|
+$16.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$23.4M |
| 2 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$22M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$21.3M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$18.7M |
| 5 |
GE
General Electric
Evendale,
Ohio
|
-$13.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
151
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$640K | -16,496 | Closed |
|
|
SSA
152
Schonfeld Strategic Advisors
New York
| – | -$510K | -13,135 | Closed |
|
153
Point72 Asset Management
Stamford,
Connecticut
| – | -$440K | -11,344 | Closed |
|
|
PG
154
PEAK6 Group
Chicago,
Illinois
| – | -$349K | -9,000 | Closed |
|
|
CCI
155
Columbus Circle Investors
| – | -$306K | -7,885 | Closed |
|
156
Tudor Investment Corp
Stamford,
Connecticut
| – | -$272K | -7,000 | Closed |
|
157
D.E. Shaw & Co
New York
| – | -$213K | -5,500 | Closed |
|
|
CG
158
Cutler Group
San Francisco,
California
| – | -$158K | -2,849 | Closed |
|
|
JG
159
Jefferies Group
New York
| – | -$82K | -2,105 | Closed |
|
160
Teacher Retirement System of Texas
Austin,
Texas
| – | -$46K | -1,198 | Closed |
|
|
MAM
161
Meeder Asset Management
Dublin,
Ohio
| – | -$46K | -1,197 | Closed |
|
|
AIM
162
Acrospire Investment Management
Chicago,
Illinois
| – | -$27K | -700 | Closed |
|
163
JP Morgan Chase
New York
| – | -$5K | -124 | Closed |
|
164
VanEck Associates
New York
| – | -$3K | -89 | Closed |
|
EGRX Hedge Fund Activity: Q3 2016 in Review
137 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2016, worth a combined $1.17B — up 75% from $667M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new EGRX positions and 28 closed out — a net gain of 21 holders — while 36 added to existing stakes and 33 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $38.2M. The largest seller was Morgan Stanley, cutting an estimated $23.4M.
- 137 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2016, up from 116 in Q2 2016.
- Funds reported $1.17B of Eagle Pharmaceuticals, Inc. stock for Q3 2016, up 75% quarter-over-quarter.
- 49 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2016 and 28 closed out, a net change of +21 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2016 was Victory Capital Management, an estimated $38.2M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2016 was Morgan Stanley, an estimated $23.4M sold.
Based on aggregated 13F filings for Q3 2016.